Skip to main content
Top
Published in: Clinical and Translational Oncology 12/2018

01-12-2018 | Review Article

This is a call to oncologists for action

Authors: C. Micó, A. Berrocal, A. Blasco, C. Caballero, V. Iranzo, M. Lobo, C. Camps

Published in: Clinical and Translational Oncology | Issue 12/2018

Login to get access

Abstract

Cancer cases are growing in an exponential way, likewise the prices of new cancer drugs. Continuing in this way, in the near future, it will be impossible to provide optimum care for all cancer patients. Therefore, it is important to establish mechanisms that enable the National Health Systems to provide the best options of treatment, either through the elaboration of decision-binding frameworks or through other initiatives that guarantee the best quality care for all oncology patients to overcome, in the best possible way, this difficult illness. Here, we review current proposals that have been established by different cancer organizations worldwide, their similarities, their differences and whether they are helpful in a real clinical setting. Facing present reality and despite these organizations’ huge efforts, these proposals are not being implemented at all and it does not seem feasible that they will in the short run. In the same way, we support and argue why oncologists should have a crucial and a preponderant role to establish the best way of guaranteeing an equal access to the latest oncology care.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef Ferlay J, Soerjomataram I, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef
4.
go back to reference Sullivan R, Peppercorn J, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80.CrossRef Sullivan R, Peppercorn J, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80.CrossRef
5.
go back to reference Stewart BW, Wild CP, editors. World cancer report. Lyon: International Agency for Research on Cancer; 2014. Stewart BW, Wild CP, editors. World cancer report. Lyon: International Agency for Research on Cancer; 2014.
6.
go back to reference Fojo T, Mailankody S. Unintended consequences of expensive cancer therapeutics. The pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140:1225–36.CrossRef Fojo T, Mailankody S. Unintended consequences of expensive cancer therapeutics. The pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140:1225–36.CrossRef
8.
go back to reference Kantarjian H, Steensma D. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10(4):e208–11.CrossRef Kantarjian H, Steensma D. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10(4):e208–11.CrossRef
9.
go back to reference Walker J. High prices for drugs attacked at meeting. Wall Street J. 2015 (Health care). Walker J. High prices for drugs attacked at meeting. Wall Street J. 2015 (Health care).
11.
go back to reference Mariotto AB, Yabroff KR, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–28.CrossRef Mariotto AB, Yabroff KR, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–28.CrossRef
13.
go back to reference Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy and costs. JAMA Oncol. 2015;1:539–40.CrossRef Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy and costs. JAMA Oncol. 2015;1:539–40.CrossRef
14.
go back to reference Howard DH, Bach PB, et al. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139–62.CrossRef Howard DH, Bach PB, et al. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139–62.CrossRef
15.
go back to reference Weeks JC, Catalano PJ, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367:1616–25.CrossRef Weeks JC, Catalano PJ, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367:1616–25.CrossRef
16.
go back to reference Prigerson HG, Bao Y, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1:778–84.CrossRef Prigerson HG, Bao Y, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1:778–84.CrossRef
17.
go back to reference Whaley C, Schneider Chafen J, et al. Association between availability of health service prices and payments for these services. JAMA. 2014;312:1670–6.CrossRef Whaley C, Schneider Chafen J, et al. Association between availability of health service prices and payments for these services. JAMA. 2014;312:1670–6.CrossRef
18.
go back to reference Wu SJ, Sylwestrzak G, et al. Price transparency for MRIs increased use of less costly providers and triggered provider competition. Health Aff. 2014;33:1391–8.CrossRef Wu SJ, Sylwestrzak G, et al. Price transparency for MRIs increased use of less costly providers and triggered provider competition. Health Aff. 2014;33:1391–8.CrossRef
19.
go back to reference Altomare I, Irwin B, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2016;12:247–8.CrossRef Altomare I, Irwin B, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2016;12:247–8.CrossRef
20.
go back to reference Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233–7.CrossRef Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233–7.CrossRef
22.
go back to reference Cherny NI, Sullivan R, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO–MCBS). Ann Oncol. 2015;26:1547–73.CrossRef Cherny NI, Sullivan R, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO–MCBS). Ann Oncol. 2015;26:1547–73.CrossRef
23.
go back to reference Cherny NI, Dafni U, et al. ESMO–magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28:2340–66.CrossRef Cherny NI, Dafni U, et al. ESMO–magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28:2340–66.CrossRef
24.
go back to reference Schnipper LE, Davidson NE, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–77.CrossRef Schnipper LE, Davidson NE, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–77.CrossRef
25.
go back to reference Schnipper LE, Davidson NE, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34:2925–34.CrossRef Schnipper LE, Davidson NE, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34:2925–34.CrossRef
26.
go back to reference Becker DJ, Lin D, et al. Exploration of the ASCO and ESMO value frameworks for antineoplastic drugs. J Oncol Pract. 2017;13(7):e653–65 Becker DJ, Lin D, et al. Exploration of the ASCO and ESMO value frameworks for antineoplastic drugs. J Oncol Pract. 2017;13(7):e653–65
30.
go back to reference Vivot A, Jacot J, et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol. 2017;28:1111–6.CrossRef Vivot A, Jacot J, et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol. 2017;28:1111–6.CrossRef
32.
go back to reference Bentley TGK, Cohen JT. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health. 2017;20:200–5.CrossRef Bentley TGK, Cohen JT. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health. 2017;20:200–5.CrossRef
34.
go back to reference World Health Organization. Health systems financing: the path to universal coverage. Geneva 2010. World Health Organization. Health systems financing: the path to universal coverage. Geneva 2010.
35.
go back to reference Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA. 2012;307:1513–6.CrossRef Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA. 2012;307:1513–6.CrossRef
37.
go back to reference Gauvreau CL, Fitzgerald NR, et al. The OncoSim model: development and use for better decision-making in Canadian cancer control. Curr Oncol. 2017;24(6):401–6.CrossRef Gauvreau CL, Fitzgerald NR, et al. The OncoSim model: development and use for better decision-making in Canadian cancer control. Curr Oncol. 2017;24(6):401–6.CrossRef
38.
go back to reference Riva S, Pravettoni G. Value-based model: a new perspective in medical decision-making. Front Public Health. 2016;4:118.CrossRef Riva S, Pravettoni G. Value-based model: a new perspective in medical decision-making. Front Public Health. 2016;4:118.CrossRef
39.
go back to reference Eaton KD, Jagels B, Martins RG. Value-based care in lung cancer. Oncologist. 2016;21:903–6.CrossRef Eaton KD, Jagels B, Martins RG. Value-based care in lung cancer. Oncologist. 2016;21:903–6.CrossRef
41.
42.
go back to reference Goulart BHL. Value: the next frontier in cancer care. Oncologist. 2016;21:651–3.CrossRef Goulart BHL. Value: the next frontier in cancer care. Oncologist. 2016;21:651–3.CrossRef
43.
go back to reference Ken Lee KH, Matthew Austin J, Pronovost PJ. Developing a measure of value in healthcare. Value Health. 2016;19:323–5.CrossRef Ken Lee KH, Matthew Austin J, Pronovost PJ. Developing a measure of value in healthcare. Value Health. 2016;19:323–5.CrossRef
44.
go back to reference Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233–7.CrossRef Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233–7.CrossRef
45.
go back to reference Altomare I, Irwin B, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2014;10:e368–72.CrossRef Altomare I, Irwin B, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2014;10:e368–72.CrossRef
46.
go back to reference Newcomer LN. Those who pay have a say: a view on oncology drug pricing and reimbursement. Oncologist. 2016;21(7):779–81CrossRef Newcomer LN. Those who pay have a say: a view on oncology drug pricing and reimbursement. Oncologist. 2016;21(7):779–81CrossRef
Metadata
Title
This is a call to oncologists for action
Authors
C. Micó
A. Berrocal
A. Blasco
C. Caballero
V. Iranzo
M. Lobo
C. Camps
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1887-3

Other articles of this Issue 12/2018

Clinical and Translational Oncology 12/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine